3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-
|
|
|
- CAS-Nr.
- 209342-40-5
- Englisch Name:
- 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-
- Synonyma:
- 100827;Finafloxacin;Finafloxacin Otic;Valine Impurity 71;Finafloxacin (Xtoro);Finafloxacin >=95% (HPLC);Finafloxacin (BAY35-3377);BAY35-3377,finafloxacin hydrochloride;8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid;8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- CBNumber:
- CB42605885
- Summenformel:
- C20H19FN4O4
- Molgewicht:
- 398.39
- MOL-Datei:
- 209342-40-5.mol
|
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Eigenschaften
- Siedepunkt:
- 686.2±55.0 °C(Predicted)
- Dichte
- 1.57±0.1 g/cm3(Predicted)
- storage temp.
- -20°C
- Löslichkeit
- DMSO : 6.4 mg/mL (16.06 mM)
- pka
- 6.38±0.50(Predicted)
- Aggregatzustand
- powder
- Farbe
- white to beige
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H340 |
Kann genetische Defekte verursachen. |
Keimzellmutagenität |
Kategorie 1B |
Achtung |
![GHS hazard pictograms]() src="/GHS08.jpg" width="20" height="20" /> |
|
|
| Sicherheit |
| P201 |
Vor Gebrauch besondere Anweisungen einholen. |
| P308+P313 |
BEI Exposition oder falls betroffen: Ärztlichen Rat einholen/ärztliche Hilfe hinzuziehen. |
|
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Finafloxacin, an antimicrobial agent of the 8-cyano subclass of
fluoroquinolones, was approved by the US FDA in December
2014 for treatment of acute otitis externa, commonly known as
swimmer’s ear, caused by susceptible strains of Pseudomonas
aeruginosa and Staphylococcus aureus. Finafloxacin was
developed by MerLion Pharmaceuticals in partnership with Bayer
Health Care Pharmaceuticals, and the drug was licensed by Mer-
Lion to Alcon (a division of Novartis) for development and commercialization
for ear infections in North America. In
contrast to other marketed fluoroquinolones, which display
reduced activity in slightly acidic environments, finafloxacin exhibits
increased antibacterial activity at pH 5–6, with minimum inhibitory
concentration values that are 4- to 8-fold lower than at
neutral pH. It is highly selective for bacterial type II topoisomerases,
which are involved in bacterial DNA replication, transcription,
repair, and recombination, and has broad spectrum
antibacterial activity against Gram-positive and Gram-negative
strains, including ciprofloxacin-resistant strains.
Verwenden
Used for the preparation of naphthyridonecarboxylic acid derivatives as drugs for therapy of Helicobacter pylori infections and associated gastroduodenal illnesses.
Definition
ChEBI: A quinolone that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted at positions 1, 6, 7 and 8 by cyclopropyl, fluoro, hexahydropyrrolo[3,4-b][1,4]oxazin-6-yl and cyano groups respectively; an antibiotic used for treatment of
acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus.
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 50)Lieferanten
209342-40-5()Verwandte Suche:
- 3-Quinolinecarboxylic acid, 8-cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2H)-yl]-1,4-dihydro-4-oxo-
- Finafloxacin
- BAY35-3377,finafloxacin hydrochloride
- 8-cyano-1-cyclopropyl-6-fluoro-7-((4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 8-Cyano-1-cyclopropyl-6-fluoro-7-[(4aS,7aS)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2H)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
- Finafloxacin (BAY35-3377)
- 100827
- (-)-(4aS,7aS)-8-Cyano-1-cyclopropyl-6-fluoro-4-oxo-7-(perhydropyrrolo[3,4-b]-1,4-oxazin-6-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- Finafloxacin >=95% (HPLC)
- Finafloxacin (Xtoro)
- Finafloxacin Otic
- (-)-(4aS,7aS)-8-Cyano-1-cyclopropyl-6-fluoro-4-oxo-7-(perhydropyrrolo[3,4-b]-1,4-oxazin-6-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride
- Valine Impurity 71
- 209342-40-5
- 209324-40-5
